Drug intelligence / Profile preview

aQII-3

Development stage: Unknown
Lead developer: CSL Seqirus
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

aQII-3 is an investigational MF59-adjuvanted quadrivalent subunit inactivated cell-derived influenza vaccine. It contains four influenza virus strains (A/H1N1, A/H3N2, B/Yamagata, and Victoria lineage) as recommended by the WHO for quadrivalent vaccines for the respective season. Developed by Seqirus, it is being evaluated in a Phase 2 clinical study for safety and immunogenicity in older adults aged 50 years and older.

Other names: Investigational aQII-3

Targets

H1N1 (Influenza A virus H1N1)

Beyond the preview

Go deeper on aQII-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aQII-3.

Explore the full profile